Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
REGN5458 for Multiple Myeloma
Recruiting1 awardPhase 1 & 2
Columbus, Ohio
This trial is testing a new drug, REGN5458, for patients with relapsed or refractory multiple myeloma who have progressed on or after 3 prior lines of therapy or who are triple-refractory. The primary objectives are to assess the safety and tolerability of REGN5458 and to determine the recommended phase 2 dose. The secondary objectives are to assess the anti-tumor activity of REGN5458, evaluate the effects of REGN5458 on health-related quality of life, and characterize the immunogenicity of REGN5458.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service